Children have a mild course of acute COVID-19 in most of the cases. However, a few non-controlled studies on children present an evaluation of long-term recovery from SARS-CoV-2 infection. Mostly, the studies were conducted on a small sample size with children aged between 0-17 years.
The study aimed to evaluate symptoms and duration of 'long COVID' in children.
Data collection was done through a nationwide cohort study with 37,522 RT-PCR verified SARS-CoV-2 infected children, aged between 0-17 years (response rate 44.9%). Further, the study also had a group of 78,037 children as control (response rate 21.3%). An electronic questionnaire was used to collect data.
It was obtained that symptoms lasting > 4 weeks were common among both SARS-CoV-2 children and controls. However, SARS-CoV-2 infected children with the age of 6-17 years reported symptoms more frequently than the control group (percent difference 0.8%).
The most reported symptoms among pre-school children were
Fatigue Risk Difference (RD) 0.05 (CI 0.04-0.06)
Loss of smell RD 0.01 (CI 0.01-0.01)
Loss of taste RD 0.01 (CI 0.01-0.02)
Muscle weakness RD 0.01 (CI 0.00-0.01)
However, in school children, respiratory problems RD 0.03 (CI 0.03-0.04), dizziness RD 0.02 (CI 0.02-0.03), chest pain RD 0.01 (CI 0.01-0.01) were also observed along with the above-mentioned symptoms.
Furthermore, children in the control group experienced significantly more concentration difficulties, headache, muscle and joint pain, cough, nausea, diarrhea and fever than SARS-CoV-2 infected.
In most of the cases, 'long COVID' symptoms resolve in children within 1-5 months. Therefore, it can be interpreted that long COVID in children is rare and mainly of short duration.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Inner Thoughts of Leonard Bernstein, the "Maestro".
2.
Mobile prostate cancer screening clinic can ID the disease in disadvantaged men
3.
No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC
4.
Parents, teachers at Missouri school want answers after string of cancer diagnoses
5.
A promising medication could slow brain tumors in children.
1.
Future-Ready Cancer Screening: What Every Clinician Should Know in 2025
2.
Cancer Evolution and Therapeutic Resistance: Mechanisms, Clinical Insights, and Emerging Strategies
3.
Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances
4.
Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases
5.
Generative AI for Adaptive Oncology Trial Design
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
5.
Current Scenario of Cancer- The Incidence of Cancer in Men
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation